Kinetics and metabolism of carbamazepine during combined antiepileptic drug therapy

Abstract

The kinetics of carbamazepine using ¹⁵N-carbamazepine were investigated in epileptic patients during combined anticonvulsant therapy. The ¹⁵N-carbamazepine plasma half-lives ranged from 5.0 to 13.6 hr with a mean of 8.2 hr. These half-lives are appreciably shorter than reported during chronic carbamazepine monotherapy. Predicted steady-state plasma levels and observed plasma levels of carbamazepine were in excellent agreement. Between 32% and 61% of the dose administered is excreted in the urine as carbamazepine-trans-diol, 5.2% to 8.8% as 9-hydroxymethyl-10-carbamoyl acridane, 1% to 1.4% as 10,-11-carbamazepine epoxide, and 0.5% as carbamazepine. The data indicate that it is the epoxide-diol pathway which is induced during long-term treatment. Concomitant therapy with primidone, phenytoin, phénobarbital, ethosuximide, or methsuximide further induces carbamazepine metabolism.